Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.65 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.65 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.64 |
| ▸ | FGB | P02675 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.64 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.64 |
| ▸ | PLEC | Q15149 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.63 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.63 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.61 |
| ▸ | UQCRB | P14927 | 2/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5047573 | 0.95 | MEN1 (0.70) | MEN1KMT2AHDAC8HDAC6HDAC2 | |
| SCHEMBL15480538 | 0.95 | MEN1 (0.71) | MEN1KMT2AHDAC8HDAC6HDAC2 | |
| SCHEMBL5943909 | 0.88 | HDAC8 (0.65) | MEN1KMT2AHDAC8HDAC6HDAC2 | |
| SCHEMBL15482013 | 0.84 | HDAC8 (0.71) | MEN1KMT2AHDAC8HDAC6HDAC2 | |
| SCHEMBL13167612 | 0.83 | KMT2A (0.80) | MEN1KMT2APOLBMAPTUQCRB | |
| SCHEMBL5944138 | 0.83 | KMT2A (0.60) | MEN1KMT2AHDAC8HDAC6HDAC2 | |
| SCHEMBL16492507 | 0.83 | CA12 (0.79) | MEN1KMT2AHDAC8HDAC6HDAC2 | |
| SCHEMBL16492508 | 0.83 | CA12 (0.79) | MEN1KMT2AHDAC8HDAC6HDAC2 | |
| SCHEMBL10093054 | 0.82 | GPR55 (0.69) | MEN1KMT2AHDAC8HDAC6HDAC2 | |
| Lithium SCHEMBL31041155 | 0.82 | KMT2A (0.77) | MEN1KMT2APOLBMAPTUQCRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | claimed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | claimed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | claimed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | MEN1 4206/4885KMT2A 100/4885HDAC8 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.